[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
July 2002

Another Potential Adjuvant Therapy for Recurrent Respiratory Papillomatosis

Arch Otolaryngol Head Neck Surg. 2002;128(7):787-788. doi:10.1001/archotol.128.7.787

RECURRENT RESPIRATORY papillomatosis (RRP) is a chronic disease of viral origin and the most common benign neoplasm of the larynx in children. However, it is still quite rare, with an incidence (new cases per year) of 0.36 to 1.11 per 100 000 and a prevalence (all cases in a year) of 1.69 to 2.59 per 100 000 in children younger than 18 years.1 Extrapolated to the US population, an estimated 80 to 1500 incident cases and 700 to 3000 prevalent cases occur in the United States each year in children younger than 18 years. Even at a tertiary care center, no single physician or center has sufficient numbers of patients to embark on randomized trials of new interventions to investigate their efficacy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×